Aptose Biosciences acquired by Hanmi Pharmaceutical for C$2.41/share; shares to be delisted

Aptose Biosciences Inc.

Total consideration ~USD$3.47M for 2,043,719 shares not already owned by Hanmi.
Premium of 28% over 30-day VWAP of C$1.88 on TSX.
All directors resigned effective June 30, 2026.
Common shares expected to be delisted from TSX on or about July 3, 2026.
Company to terminate reporting obligations in US and Canada.

item 2.01 item 3.03 item 5.01 item 5.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.